drugset / Trial / NCT04354805

Administration of Chlorpromazine as a Treatment for COVID-19

NCT04354805

RandomizedParallel-groupSingle-blindTreatment

Summary

In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe pneumonia will be treated with chlorpromazine. The improvement in clinical \& laboratory manifestations will be evaluated in treated patient compared to control group.

Timeline

Start
2020-08-01
Primary completion
2020-10
Completion
2020-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorpromazine Small molecule 100 mg Oral

Indications